Cygnus Technologies, LLC
Carolin Brunner is a Quality Control Analyst II at Cygnus Technologies, LLC, since September 2022, where responsibilities include testing in-process and incoming biological materials using ELISA assays and standardized protocols, while following established SOPs for material approval or rejection. Previously, Carolin served as an Undergraduate Research Assistant at Syracuse University College of Arts and Sciences from September 2020 to March 2022, gaining proficiency in Python programming to develop a Machine Learning algorithm for analyzing electropherograms. Early work experience includes roles as a Receptionist at Sublime Hair Studio in summer 2021 and as a Crew Member at Fiber Flame Studio from June 2016 to January 2020. Carolin holds a Bachelor of Science in Biology from Syracuse University and graduated from Onteora High School in 2018.
Cygnus Technologies, LLC
Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes. Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process. Located in Southport, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.